Fundamental Analysis Stories
What is Castor Maritime (USA Stocks:CTRM) earnings potential based on the recent fundamentals?
 | 20 hours ago at Macroaxis By Aina Ster |
A rising tide lifts all boats, but understanding the fundamentals behind a company's performance is key to navigating its true potential. Castor Maritime (NASDAQ: CTRM), operating within the marine transportation sector, presents a compelling case for investors willing to look beyond the surface. With a total stockholder equity of approximately $570 million and an EBITDA of around $34.5 million, the company shows signs of operational stability. Continue Reading...
- CTRM Castor Maritime
- Latest At least 180 aircrew pursuing Ministry of Defence after cancer diagnoses
- CTRM 2.2 0.07
- Low 2.11
- High 2.23
- Alpha -0.094
- Beta 0.16
- Return On Equity 0.0269
- Return On Asset 0.0013
- Profit Margin 0.22 %
- Operating Margin (0.39) %
- Current Valuation 53.27 M
- Shares Outstanding 9.66 M
- Shares Owned By Institutions 4.20 %
- Number Of Shares Shorted 45.55 K
- Price To Earning 1.51 X
- Price To Book 0.04 X
- Price To Sales 0.33 X
- Revenue 66.24 M
- Gross Profit 35.27 M
- EBITDA 34.53 M
- Net Income 15.3 M
- Cash And Equivalents 133.89 M
- Cash Per Share 1.41 X
- Total Debt 111.32 M
- Debt To Equity 0.32 %
- Current Ratio 3.67 X
- Book Value Per Share 50.96 X
- Cash Flow From Operations 41.91 M
- Short Ratio 0.78 X
- Earnings Per Share 0.38 X
- Number Of Employees 155
- Beta 0.77
- Market Capitalization 21.93 M
- Total Asset 797.38 M
- Retained Earnings 228.53 M
- Working Capital 189.46 M
- Current Asset 7.72 M
- Current Liabilities 3.7 M
- Net Asset 797.38 M
- Accumulation Distribution 0.0538
- Daily Balance Of Power 0.5833
- Rate Of Daily Change 1.03
- Day Median Price 2.17
- Day Typical Price 2.18
- Market Facilitation Index 0.12
- Price Action Indicator 0.065
- Period Momentum Indicator 0.07
- Relative Strength Index 45.48
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
A penny saved is a penny earned, but for Qualigen Therapeutics (NASDAQ: QLGN), the current financial picture suggests more pennies are slipping away than coming in. The company is operating with a negative gross profit of around $4.5K and a net loss of approximately $8.42 per share, reflecting ongoing challenges in turning revenue into profitability. Its enterprise value sits at roughly $3.7M, with total debt of about $1.3M and cash reserves close to $402K, indicating limited liquidity.
| few days ago at Macroaxis By Raphi Shpitalnik |  |
In today’s software development ecosystem, social media APIs have become essential tools for building modern, connected applications. From integrating live content to automating publishing workflows or pulling real-time analytics, these APIs open powerful pathways to engage with digital audiences. If you're looking for more on what social data can enable, you can learn more at Data365.
| few days ago at Macroaxis By Aina Ster | |
Seeing the forest for the trees can be a challenge when evaluating investment opportunities, but Neonode stands out with its unique position in the technology sector. Despite reporting a loss of 5.9 million before tax, the company maintains a solid cash reserve of 12.43 million, providing a cushion for future growth initiatives. As a player in the electronic components industry, Neonode's innovative approach and strategic focus could offer investors a chance to tap into a promising market segment.
| over a week ago at Macroaxis By Ellen Johnson |  |
Strike while the iron is hot, especially when it comes to potential growth opportunities in the biotech sector. Lyra Therapeutics, trading on NASDAQ under the ticker LYRA, has been catching the eye of investors with its recent surge. Despite reporting a net income loss of 93.4M from continuing operations, the company holds a solid net asset base of 66.35M and cash reserves of 40.6M, providing a cushion for future endeavors.
| over three weeks ago at Macroaxis By Rifka Kats |  |
To attract serious capital, content marketing for cryptocurrency projects must rise above generic hype and empty jargon. Elevating credibility means integrating real insights—rooted in tokenomics, market data, and financial logic—into every aspect of communication. This isn’t a luxury; it’s the baseline for projects that want to be taken seriously by discerning investors.
| over three weeks ago at Macroaxis By Aina Ster | |
To attract serious capital, content marketing for cryptocurrency projects must rise above generic hype and empty jargon. Elevating credibility means integrating real insights—rooted in tokenomics, market data, and financial logic—into every aspect of communication. This isn’t a luxury; it’s the baseline for projects that want to be taken seriously by discerning investors.
| over three weeks ago at Macroaxis By Aina Ster | |
Im Cannabis Corp, trading on NASDAQ under the ticker IMCC, presents a mixed bag of fundamentals that investors should carefully consider. Despite a recent surge in its stock price, the company faces challenges with a net income from continuing operations showing a loss of 11.8M. The cost of revenue stands at 45.6M, which significantly overshadows its gross profit of 8.5M, indicating pressure on margins.
| over a month ago at Macroaxis By Raphi Shpitalnik | |
Our recommendation tool can help you cross-check the current analyst consensus on SiriusPoint and assess the company's growth potential in today's economic climate. While SiriusPoint isn't expected to pay dividends this year, as it focuses on preserving or reinvesting funds, this doesn't mean the stock lacks potential. Investing in non-dividend-paying stocks can still be rewarding through capital appreciation.
| over a month ago at Macroaxis By Aina Ster | |
National Research Corp's financial health presents a mixed picture, with a solid operating income of 35.2M suggesting robust core operations, yet a net working capital loss of 16.3M raises questions about its short-term financial flexibility. This duality might indicate a temporary setback, but for investors with a keen eye on fundamentals, it could also signal a strategic buying opportunity if the company can effectively manage its liquidity challenges.
Important Points
Our investment recommendation tool allows us to verify current analyst opinions on National Research Corp and assess its growth potential in today's economic climate. The company's dividends can offer insights into the stock's current value, with an expected annual dividend income of approximately $0.69 per share.| over a month ago at Macroaxis By Aina Ster | |